Thoracic Cancer
Conditions
Keywords
opioid free anesthesia, non small cell lung caner
Brief summary
to investigate the efficacy and safety of opioid-free anesthesia for non-small-cell lung cancer resection and its underlying clinical value
Detailed description
Opioids used to have its irreplaceable role in standard opioid-based anesthesia, yet with the help of hypnotics, local anesthetics, anti-inflammatory drugs, α-2 agonists and epidural techniques, opioid-free anesthesia (OFA) has been proved to be safe and feasible for non-cardiac major surgeries. Opioid-sparing anesthesia (OSA) is encouraged by the needs of enhanced recovery and recommended by the latest guidelines for anesthesia of lung surgery. According to previous studies, both opioid-sparing and opioid-free anesthesia would reduce the incidence of opioid-related adverse events and speed up the postoperative recovery to some extent, yet no studies ever are dedicated to compare these two different techniques.
Interventions
PROCEDUREopioid free anesthesia
Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
PROCEDUREOpioid-sparing anesthesia
patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* going through thoracoscopic lung surgery including lobectomy, segmentectomy, single or multiple wedge resection, and two of the above procedures combined; * able to complete the pain scoring face-to-face; * no cognitive dysfunction or history of anesthetic drug allergy; * ASA grade I-II
Exclusion criteria
-psychological disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| acute postoperative pain scores | day1 postoperation | visual analog scale was used |
| occurrence of postoperative opioid-related adverse events | day1 postoperation | occurrence of postoperative opioid-related adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PCEA bolus consumption | within 48hours | PCEA bolus consumption |
| need for rescue intravenous opioids or any type of painkiller | within 48hours | need for rescue intravenous opioids or any type of painkiller |
| relapse free survival and overall survival | within 5 years | relapse free survival and overall survival |
| Pathologic results and TNM rating | within one month | Pathologic results and TNM rating |
| hospital length of stay and total hospital expenses | within 10days | hospital length of stay and total hospital expenses |
| occurrence of episodes of postoperative pain (VAS ≥4) | within 48hours | occurrence of episodes of postoperative pain (VAS ≥4) |
Countries
China
Contacts
Primary ContactSHUWEI WANG
Outcome results
None listed